What is Sermorelin? What it does, benefits and what the evidence shows

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release the body's own growth hormone. It's the rare compound in this category that actually held FDA approval — sold under the brand name Geref from 1990 and 1997 until its manufacturer, EMD Serono, notified FDA in 2008 that it was discontinuing it; FDA withdrew the applications effective June 18, 2009. FDA later confirmed in the Federal Register that the withdrawal was not for reasons of safety or effectiveness. Today there's no FDA-approved sermorelin product on the market; what's sold is either compounded through a pharmacy or sourced through the grey market. This isn't medical advice.

What sermorelin is and how it works

Sermorelin acetate is the first 29 amino acids of human GHRH, the natural hormone that signals the pituitary gland to release growth hormone. Like GHRH itself, it binds GHRH receptors on pituitary somatotroph cells and stimulates them to secrete growth hormone, and — unlike growth hormone itself — it does this in a way that stays subject to the body's own negative feedback loop through somatostatin, the hormone that normally reins in GH secretion when levels run high (Walker, Clinical Interventions in Aging, 2006). Because it depends on the pituitary's somatotroph cells still having some ability to respond, it doesn't work in people whose pituitary can't secrete GH at all, only in those with at least partial function.

Sermorelin was marketed in the US under two New Drug Applications sponsored by EMD Serono: NDA 19-863 (approved December 28, 1990) and NDA 20-443 (approved September 26, 1997) (Federal Register, 2013 determination). Per FDA's own citation of the Geref label elsewhere in its regulatory record, the approved uses were narrow: a stimulation test to help evaluate whether the pituitary gland could secrete growth hormone, and treatment of growth failure specifically in pediatric patients with idiopathic growth hormone deficiency who responded adequately to that stimulation test — children with other causes of GHD, such as surgery or congenital conditions, were not covered by the approval (cited in FDA's 2024 ipamorelin evaluation memorandum, footnote 62). EMD Serono notified FDA in mid- and late 2008 that it was discontinuing both formulations, and FDA announced the withdrawal of both NDAs in 2009, effective June 18 of that year. In a subsequent 2013 Federal Register notice — issued in response to a citizen petition dated October 12, 2012, and important because a finding that a drug wasn't withdrawn for safety reasons opens the door to generic approval — FDA formally determined that the GEREF (Sermorelin Acetate) injection products "were not withdrawn from sale for reasons of safety or effectiveness." A separate FDA-funded review by the University of Maryland's Center of Excellence in Regulatory Science and Innovation reached the same conclusion in 2020: sermorelin acetate "was available as an FDA-approved injectable product that was discontinued, not for reasons of safety or efficacy," and as of that review there was no FDA-approved sermorelin product available in the US or in the other countries and regions the reviewers checked.

What people use it for

What the research actually shows

An approval that existed, and a discontinuation that wasn't about safety

Sermorelin's regulatory history is unusual for this category precisely because there's a real approval to point to. FDA approved Geref twice — first as a diagnostic stimulation test in 1990, then as a pediatric growth-failure treatment in 1997 — and both approvals stayed in effect for roughly two decades before EMD Serono chose to stop making it. The company's own withdrawal notifications to FDA in 2008 didn't cite safety or efficacy problems, and FDA's subsequent formal determination confirmed there wasn't one: the 2013 Federal Register notice states plainly that the relevant Geref products "were not withdrawn from sale for reasons of safety or effectiveness." A peer-reviewed 2006 commentary on sermorelin frames the practical reason for the withdrawal as competitive rather than clinical, and says sermorelin "failed as a growth-promoting agent in children." The commentary's reasoning: sermorelin "could not compete with rhGH," because growth-deficient children need higher doses of growth hormone than can be achieved by stimulating production of their own hormone, which is what sermorelin does. The commentary argues that the same feature that made sermorelin commercially unattractive against rhGH — that it can't force GH output past what the gland's own feedback loop allows — is also the reason its safety profile differs from directly injected GH.

The approved indications were narrower than "growth hormone deficiency" in general

It's worth being precise about what Geref's approval actually covered, because "approved for growth hormone deficiency" oversimplifies it. FDA's own regulatory record specifically notes that the pediatric treatment indication applied only to children with idiopathic GHD who responded adequately on the Geref stimulation test itself — children whose GHD came from another cause, such as surgery, congenital conditions or infections, weren't covered. FDA's reviewers also flag, in the context of a separate 2024 evaluation of a different peptide, that the stimulation test used to determine eligibility for Geref therapy "is not a validated test for the diagnosis of partial GHD," and that growth hormone assay technology has changed enough since Geref's approval that the same numeric thresholds used then might not apply the same way with modern testing. None of that changes the historical fact of approval, but it's a meaningfully narrower claim than "sermorelin is an FDA-approved treatment for low growth hormone."

Adult anti-aging, muscle, fat loss, and sleep claims — advocacy, not trial evidence

Some published commentary makes the case that sermorelin could be repurposed for age-related decline in growth hormone secretion, arguing its feedback-dependent mechanism makes it inherently safer than direct GH replacement for that population (Walker, Clinical Interventions in Aging, 2006). That's a physician's argument for why the mechanism might be advantageous, not a controlled trial showing it improves any specific outcome in older or healthy adults — the same article that makes this case does not report a clinical trial testing sermorelin for muscle mass, fat loss, sleep, or any other anti-aging outcome. We found no published randomized, placebo-controlled human trial testing sermorelin for any of the benefits commonly claimed for it outside its original, now-discontinued, approved uses.

Side effects and risks

Because Geref has been off the market since 2009, there's no current FDA-maintained safety monitoring or updated label reflecting real-world use, and the published safety data we could verify is old and comes from the pediatric program. A 1999 review of sermorelin in children reported it was well tolerated, with transient facial flushing and injection-site pain the most commonly reported adverse events (Prakash and Goa, BioDrugs, 1999), and a one-year multicenter study in 110 children reported no adverse changes in routine blood chemistry or hormone measures (Thorner et al., J Clin Endocrinol Metab, 1996). Neither speaks to adults using it for anti-aging, or to compounded or grey-market product. What is verified is the regulatory framing: FDA and the FDA-funded University of Maryland review both describe the original withdrawal as unrelated to safety, which is a statement about the decision to stop selling it, not a comprehensive modern safety profile for the compound as currently compounded or sold on the grey market.

Because sermorelin only prompts the pituitary to release GH within the limits of the body's own feedback loop, the theoretical case for it being gentler than directly injected growth hormone is real, but it hasn't been tested against modern compounded or grey-market products specifically. Compounded and grey-market sermorelin also isn't subject to the manufacturing oversight that applied to the original FDA-approved Geref, which is a separate risk from the biology of the peptide itself — one our lab-testing data below can speak to more directly than the medical literature can.

What the lab tests show

As of September 30, 2026, our database includes 11 sermorelin vials from 5 vendors, drawn from 9 lab reports dated December 2024 through August 2026. 11 of the 11 vials had a purity result, and 10 came in at 99% or higher, with a median of 99.31%. As of September 29, 2026, dose accuracy was the standout figure here: the median measurement ran just 1.2% over label, with 9 of 11 vials landing within ±5% of label and all 11 within ±10% — making sermorelin, in our data so far, the most consistently label-accurate compound we track. No vial in this set failed our definition.

As of September 29, 2026, that's still a small sample across only five vendors, so a single new batch of reports could shift these numbers — treat it as an encouraging snapshot, not a guarantee about any specific vendor going forward. Here's how the ranked vendors for sermorelin look right now; the table shows current verdicts and flags any vendor whose failed-vial rate is above 5%. Ranked isn't automatically good, and for a compound with this few total vials tested, this table may be short:

Buying smarter

If you're evaluating a specific vendor's sermorelin, check their full record on our sermorelin results page — a vendor needs five or more lab reports before we rank them, and the number of reports behind a score matters as much as the score itself. Given how consistent this compound's dose accuracy has looked so far, a purity check may be the more informative test if you're deciding what to verify first, though how to get a peptide tested covers ordering identity, purity, and quantity testing together. Whatever COA a vendor posts is a starting point, not proof: check it against how to read a peptide COA and the red flags in fake peptide COAs.

Sermorelin is often discussed alongside CJC-1295 and ipamorelin as growth-hormone-releasing peptides sold in the same grey market — each works through a different mechanism and has a different evidence base, so it's worth reading about the specific one you're actually considering. If your own report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; sermorelin is currently sold for research use only and is not available as an FDA-approved drug product in the United States.